Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
NEU.AX Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: April 07, 2026
Report Source: 2025 Annual Report
Neuren Pharmaceuticals Ltd. Stock Analysis NEU.AX
Australia Health Care Small Cap Report: Neuren Pharmaceuticals Ltd. engages in the development of new therapies for neurodevelopmental disorders that emerge in early childhood. The company is headquartered in Hawthorn, Victoria. The company went IPO on 2005-02-03. The firm is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product, NNZ-2591, is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The firm has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.
Read More Neuren Pharmaceuticals Ltd (NEU.AX) Chart
Key Statistics of Neuren Pharmaceuticals Ltd (NEU.AX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
AUD12.52Volume
362.59KP/E Ratio (TTM)
51.7352 Week Range
Market Cap
1.57BAvg. Volume
119.58KDividend Yield
-Financial Metrics & Statements of Neuren Pharmaceuticals Ltd (NEU.AX)
FAQ's for Neuren Pharmaceuticals Ltd (NEU.AX)
- According to Musaffa’s Shariah screening methodology, Neuren Pharmaceuticals Ltd (NEU.AX) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Neuren Pharmaceuticals Ltd using these criteria to determine its compliance status.
- Muslim investors may consider investing in Neuren Pharmaceuticals Ltd if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Neuren Pharmaceuticals Ltd by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Neuren Pharmaceuticals Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Neuren Pharmaceuticals Ltd on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.